Oxford BioMedica
Discover Realise

Press releases

14/06/2017
Oxford BioMedica Notes Findings on CTL019 from Phase II JULIET Study Presented at the 14th Meeting of International Conference on Malignant Lymphoma (ICML)
Read more
 
07/06/2017
Oxford BioMedica notes FDA Advisory Committee to review CTL019
Read more
 
06/06/2017
Oxford BioMedica to Webcast Presentation at the Jefferies 2017 Healthcare Conference New York
Read more
pdf
30/03/2017
Oxford BioMedica notes acceptance by FDA of a Biologics License Application (BLA) filing for CTL019
Read more
 
27/03/2017
Oxford BioMedica Announces Publication in the Journal Nature Communications on Study Results Supporting the Transgene Repression in vector Production (TRiP) system
Read more
pdf
16/03/2017
OXFORD BIOMEDICA PLC PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2016
Read more
 
28/02/2017
Appointment of New Chief Financial Officer
Read more
 
24/02/2017
Oxford BioMedica Notes Encouraging Results of the Investigator Led Phase I/II clinical trial of MVA-5T4 Immunotherapy (TroVax®) and Low Dose Cyclophosphamide in Patients with Advanced Colorectal Cancer
Read more
 
05/12/2016
Oxford BioMedica Notes Findings Reported by Novartis on CTL-019 at 58th American Society of Hematology Annual Meeting
Read more
 
29/11/2016
Oxford BioMedica Announces a Strategic Alliance with Orchard Therapeutics
Read more
 
10/10/2016
Oxford BioMedica Announces Publication of Pioneering RetinoStat® (OXB-201) Phase I Study Data in the Journal, Human Gene Therapy
Read more
 
29/09/2016
Oxford BioMedica Result of General Meeting and Directors Dealing
Read more
pdf
13/09/2016
Oxford BioMedica Interim Results Replay
Read more
 
13/09/2016
Proposed fundraising of £10 million by way of a placing, subscription and related party transaction
Read more
pdf
13/09/2016
Interim Results for the six months ended 30 June 2016
Read more
pdf

Facts

Our potential

Our success will be reflected in the returns we can achieve for those who have trusted and invested in our potential


Novel products

Our product candidates have the potential to transform treatment landscapes